Cet anticorps Souris Monoclonal détecte spécifiquement Abciximab Biosimilar dans FACS et in vivo. Il présente une réactivité avec des échantillons de Humain.
Abciximab Biosimilar uses the same protein sequences as the therapeutic antibody abciximab. Abciximab, a glycoprotein IIb/IIIa receptor antagonist, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor. While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.
Purification
Protein A or G affinity column
Pureté
>95 % by reducing SDS-PAGE
niveau d'endotoxine
< 1 EU per 1 mg of the protein by the LAL method
Immunogène
Human Glycoprotein IIb/IIIa Receptor
Indications d'application
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Format
Liquid
Concentration
> 3 mg/mL
Stock
4 °C,-20 °C
Stockage commentaire
Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.